Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
15.51
-0.35 (-2.21%)
At close: May 18, 2026, 4:00 PM EDT
15.50
-0.01 (-0.06%)
Pre-market: May 19, 2026, 6:26 AM EDT
Nurix Therapeutics Employees
Nurix Therapeutics had 317 employees as of November 30, 2025. The number of employees increased by 31 or 10.84% compared to the previous year.
Employees
317
Change (1Y)
31
Growth (1Y)
10.84%
Revenue / Employee
$226,432
Profits / Employee
-$931,483
Market Cap
1.60B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Nov 30, 2025 | 317 | 31 | 10.84% |
| Nov 30, 2024 | 286 | 2 | 0.70% |
| Nov 30, 2023 | 284 | -13 | -4.38% |
| Nov 30, 2022 | 297 | 55 | 22.73% |
| Nov 30, 2021 | 242 | 107 | 79.26% |
| Nov 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Agios Pharmaceuticals | 540 |
| Vericel | 398 |
| Viridian Therapeutics | 252 |
| Capricor Therapeutics | 231 |
| uniQure | 221 |
| Precigen | 160 |
| Innoviva | 159 |
NRIX News
- 4 days ago - Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting - GlobeNewsWire
- 6 days ago - Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 days ago - Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress - GlobeNewsWire
- 27 days ago - Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026 - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 5 weeks ago - Nurix Therapeutics price target lowered to $28 from $29 at Wells Fargo - TheFly
- 5 weeks ago - Nurix Therapeutics price target lowered to $34 from $35 at Stifel - TheFly
- 5 weeks ago - Nurix Therapeutics reports Q1 EPS (79c), consensus (76c) - TheFly